Cohort Studies Suggesting Immediate HAART Confers No Extra Benefit Compared with Deferred HAART in HIV-Infected Persons CD4 >200 cells/mm3
From Treatment Action Group
March 2000
A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!
| Study |
N |
Reference |
| EuroSIDA |
7,331 |
Phillips, 1999 |
| Swiss Cohort |
3,342 |
AIDS, 1999 |
| ICONA (Italy) |
805 |
Phillips, 1999 |
| Frankfurt Cohort |
536 |
Phillips, 1999 |
| Royal Free |
500 |
Phillips, 1999 |
| Hemophilia Cohort |
A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!
This article was provided by Treatment Action Group. It is a part of the publication TAGline.
Email
Print-Friendly
Glossary
